1. Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta‐analysis of data from randomized placebo‐controlled trials. Issue 10 (24th August 2016) Authors: Salsali, A.; Kim, G.; Woerle, H. J.; Broedl, U. C.; Hantel, S. Journal: Diabetes, obesity & metabolism Issue: Volume 18:Issue 10(2016) Page Start: 1034 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Issue 12 (9th October 2015) Authors: Chilton, R.; Tikkanen, I.; Cannon, C. P.; Crowe, S.; Woerle, H. J.; Broedl, U. C.; Johansen, O. E. Journal: Diabetes, obesity & metabolism Issue: Volume 17:Issue 12(2015:Dec.) Page Start: 1180 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16‐week, randomized, placebo‐controlled trial. Issue 7 (13th May 2015) Authors: Ross, S.; Thamer, C.; Cescutti, J.; Meinicke, T.; Woerle, H. J.; Broedl, U. C. Journal: Diabetes, obesity & metabolism Issue: Volume 17:Issue 7(2015:Jul.) Page Start: 699 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Empagliflozin as add‐on to metformin in people with Type 2 diabetes. Issue 12 (14th July 2015) Authors: Merker, L.; Häring, H‐U.; Christiansen, A. V.; Roux, F.; Salsali, A.; Kim, G.; Meinicke, T.; Woerle, H. J.; Broedl, U. C. Journal: Diabetic medicine Issue: Volume 32:Issue 12(2015:Dec.) Page Start: 1555 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4‐week, randomized, placebo‐controlled trial (EASE‐1). Issue 10 (24th June 2015) Authors: Pieber, T. R.; Famulla, S.; Eilbracht, J.; Cescutti, J.; Soleymanlou, N.; Johansen, O. E.; Woerle, H. J.; Broedl, U. C.; Kaspers, S. Journal: Diabetes, obesity & metabolism Issue: Volume 17:Issue 10(2015:Oct.) Page Start: 928 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial. Issue 2 (22nd August 2013) Authors: Kovacs, C. S.; Seshiah, V.; Swallow, R.; Jones, R.; Rattunde, H.; Woerle, H. J.; Broedl, U. C. Journal: Diabetes, obesity & metabolism Issue: Volume 16:Issue 2(2014:Feb.) Page Start: 147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial. Issue 10 (14th July 2015) Authors: Rosenstock, J.; Jelaska, A.; Zeller, C.; Kim, G.; Broedl, U. C.; Woerle, H. J.; on behalf of the EMPA‐REG BASALTM trial investigators Journal: Diabetes, obesity & metabolism Issue: Volume 17:Issue 10(2015:Oct.) Page Start: 936 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Long‐term treatment with empagliflozin as add‐on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus. Issue 7 (15th April 2015) Authors: Araki, E.; Tanizawa, Y.; Tanaka, Y.; Taniguchi, A.; Koiwai, K.; Kim, G.; Salsali, A.; Woerle, H. J.; Broedl, U. C. Journal: Diabetes, obesity & metabolism Issue: Volume 17:Issue 7(2015:Jul.) Page Start: 665 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Mixed‐effects modelling to quantify the effect of empagliflozin on renal glucose reabsorption in patients with type 2 diabetes. Issue 3 (15th January 2016) Authors: Mondick, J.; Riggs, M.; Sasaki, T.; Sarashina, A.; Broedl, U. C.; Retlich, S. Journal: Diabetes, obesity & metabolism Issue: Volume 18:Issue 3(2016) Page Start: 241 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Issue 3 (19th August 2013) Authors: Macha, S.; Mattheus, M.; Halabi, A.; Pinnetti, S.; Woerle, H. J.; Broedl, U. C. Journal: Diabetes, obesity & metabolism Issue: Volume 16:Issue 3(2014:Mar.) Page Start: 215 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗